Key result
A systematic review of implantable cardioverter-defibrillator deactivation in heart failure found low occurrence of discussions, patient knowledge gaps, and provider hesitation.
Why the study?
What are the barriers to the deactivation of implantable cardioverter-defibrillators in patients with end-stage heart failure at the end of life?
Systematic Review
What are the barriers to the deactivation of implantable cardioverter-defibrillators in patients with end-stage heart failure at the end of life?
There is a critical need for improved patient and provider education, periodic discussions, and institutional protocols regarding ICD deactivation at the end of life in heart failure patients.
Barriers to ICD deactivation warrant immediate provider training and patient education in end-stage HF; confirms persistent gaps and leaves open optimal intervention strategies.
Implantable cardioverter-defibrillator aids in the prevention of cardiac arrest by delivering an electrical shock in the presence of life-threatening ventricular arrhythmias. Although implantable cardioverter-defibrillators are essential to sustain life in patients with end-stage heart failure, it is important to consider the option for prompt deactivation of implantable cardioverter-defibrillators to prevent inappropriate electrical shocks at the end of life where death is inevitable. In this systematic review, available literature was reviewed, using six electronic databases, to identify problems that may delay the deactivation of implantable cardioverter-defibrillators and address possible considerations for implantable cardioverter-defibrillator management to improve end-of-life care. Studies reported low occurrence of deactivation discussions, lack of knowledge regarding implantable cardioverter-defibrillator deactivation among most patients, and provider's perception of being unqualified to initiate discussion and perform deactivation of implantable cardioverter-defibrillator. A need for additional patient and provider education and periodic discussions between patient and provider on implantable cardioverter-defibrillator deactivation should occur, as well as development of protocol or policy to guide care at the end of life.
No takes yet. Share an insight, caveat, or question.
Herman et al. (2018) conducted a systematic review in End-stage heart failure. Implantable cardioverter-defibrillator deactivation was evaluated on Problems delaying deactivation and considerations for management. A systematic review of implantable cardioverter-defibrillator deactivation in heart failure found low occurrence of discussions, patient knowledge gaps, and provider hesitation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: